CRISPR Therapeutics AG — Earnings Quality Grade C
CRSP · Healthcare
Some red flags
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
Insufficient data
AR growth -100.0% vs revenue growth -100.0%
Revenue -100.0%, CFFO -141.7%. Cash follows revenue
Expense Quality
No material inventory
CapEx growth 1263.2% is >2x revenue growth -100.0%
SG&A/Gross Profit = -34.4%, excellent (<30%)
Gross margin swung -309.6pp (64.8% → -244.8%)
Cash Flow Quality
CFFO/NI = 0.59. Below 1.0
FCF is negative ($-0.4B)
Accruals ratio = -10.4%. Low accruals
Cash $2.0B covers debt $0.2B
Balance Sheet Health
No goodwill. Clean balance sheet
Debt/EBITDA = -0.3x. Healthy
Other assets 17.0% vs revenue -100.0%. Normal
No write-off data
Acquisition Risk
FCF after acquisitions negative for 3 years
No goodwill
Manipulation Score
Calculation error: float division by zero
Portfolio monitoring
Monitor CRSP continuously
The full checks and model details are free to read. Use Watchlist to track your holdings; Pro adds automatic quarterly rescoring, risk-event email alerts, scans up to 50 tickers, and export workflows.
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25